Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Profile gets US nod for inhaled therapies technology:

This article was originally published in Clinica

Executive Summary

UK firm Profile Therapeutics has received US FDA approval to sell its second-generation adaptive aerosol delivery (AAD) system, Prodose. The product is already available in Europe to deliver Promixin, an inhaled antibiotic for treating patients with cystic fibrosis, and Ventavis, Schering AG's product for pulmonary hypertension. It has also been selected regarding the development of CoTherix' inhaled Iloprost for pulmonary hypertension. A third-generation system, Prodose HandHeld, is in its final stages of development and is expected to be available to patients this year, said Bognor Regis, West Sussex-based Profile Therapeutics. The company is currently in discussions regarding an offer being made for the firm.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts